secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-08-22T23:59:59+00:00
Accession:  0000950103-22-014273
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen completes sale of Trans Ova Genetics for $170M upfront plus up to $10M earn-out
--------------------------------------------------------------------------------

- Sale closed on August 18, 2022; buyer is Spring Bidco LLC (URUS). Net proceeds ~$169.5M after adjustments.
- Company plans to use $200M (including proceeds) to pay senior convertible notes and for other permitted purposes.
- Up to $10M earn-out based on Trans Ova performance in 2022-2023, payable in cash.
- Divestiture allows Precigen to focus on its core gene and cell therapy pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322014273/0000950103-22-014273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322014273/dp178880_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-014273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer